 patients on statins and 15% among
those not on statins at the time of the CAS (odds ratio
[OR], 0.23; 95% CI, 0.005-0.99; P ¼ .049).94 This ﬁnding
was conﬁrmed in a study of 344 consecutive patients
who underwent CAS from 2002 to 201